Tyza

Quick links to important sections

Tyza

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tyza

Property Description
Active Ingredient Terbinafine Hydrochloride
Form Oral Tablet, Topical Cream
Pharmacological Class Allylamine Antifungal Agent
General Purpose To eliminate fungal pathogens
Origin Synthetic Derivative

Defining Tyza: An Allylamine Antifungal Agent

Tyza is a medication whose active component is Terbinafine Hydrochloride, officially classified as a synthetic allylamine antifungal agent. This substance is provided as a single-ingredient product designed to target infections caused by various fungal organisms, particularly dermatophytes. The classification as an allylamine derivative is crucial, as pharmacological studies have clinically recognized this group for its superior efficacy against these prevalent skin and nail pathogens. This confirms the agent's established and highly targeted role.

The medication's fundamental purpose is to achieve a fungicidal effect, meaning it actively causes the death of the fungal cells, which ensures a definitive approach to infection resolution. Research confirms that the allylamine class is specifically recognized for its potent ability to kill susceptible fungi directly.


Terbinafine's Core Action and General Purpose

Terbinafine's general function is to resolve infections by actively compromising the fungal cell's structural integrity. The core action involves inhibiting the enzyme squalene epoxidase, a critical step in the fungal cell's ability to produce ergosterol. By interfering with this process, Terbinafine disrupts the manufacturing of this sterol, which is essential for maintaining the structure and function of the fungal cell membrane.

This targeted inhibition leads to structural instability and the toxic accumulation of the precursor squalene within the cell. This provides the medication with its powerful fungicidal effect, which is the general purpose supporting its use in eliminating fungal growth, for instance, when addressing a persistent foot fungus (tinea pedis).


Tyza: Available Forms for Systemic and Topical Use

To treat the spectrum of fungal infections effectively, Terbinafine Hydrochloride is formulated into two distinct high-level preparations: the oral tablet and the topical cream. The oral tablet is intended for systemic use, requiring the medication to be absorbed into the bloodstream to reach and address deeper, more widespread infections throughout the body. In contrast, the topical cream is designed for dermatological application, providing a high concentration of the active ingredient directly to the skin surface to address localized, superficial fungal conditions.

Regulatory References

  1. NIH DailyMed

What side effects are possible with Tyza?

Possible Side Effects and Safety Information

The official regulatory documentation for oral Terbinafine Hydrochloride lists various possible side effects, categorized by frequency and the body system affected. According to regulatory labeling, several reactions are classified as Very Common, potentially affecting more than 1 in 10 individuals. These commonly reported effects include headache, a range of gastrointestinal symptoms (such as dyspepsia, nausea, diarrhea, and abdominal pain), rash, urticaria, decreased appetite, and musculoskeletal reactions like arthralgia and myalgia.

Safety concerns documented in postmarketing experience highlight the potential for serious adverse reactions. These rare, yet critical, events include cases of liver failure, which in some instances have led to the need for liver transplant or death, and serious skin/hypersensitivity reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Very rare cases of blood disorders affecting the blood and lymphatic system, including neutropenia and pancytopenia, have also been reported.

Regarding the nervous system, potential effects include taste disturbance (ageusia or hypogeusia), which may, in rare cases, be prolonged or permanent. Hepatotoxicity is documented to occur, on average, within the first 6 weeks of therapy.

Population-specific safety statements dictate that the medication is not recommended for individuals with chronic or active liver disease. Furthermore, its use is not recommended in patients with renal impairment where the creatinine clearance is le50 mL/min. The medication has also been associated with the precipitation or exacerbation of pre-existing lupus erythematosus or psoriasis.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented information regarding overexposure to Terbinafine Hydrochloride, based strictly on government regulatory documents, such as FDA prescribing information and SmPC.

Documented Overdose Manifestations

Suspected overexposure to the oral tablet may present with a documented profile of non-specific symptoms. These manifestations primarily include gastrointestinal effects such as nausea, vomiting, and abdominal pain (epigastric pain). Additionally, central nervous system effects such as headache and dizziness have been reported, alongside symptoms like rash and frequent urination.

The regulatory profile indicates that no specific antidote is known for this overdose. Treatment is officially defined as symptomatic supportive therapy and the elimination of the active substance, which may involve the administration of activated charcoal.

Overdose Risk & Action Regulatory Statement
Exposure Likelihood Overdose from the topical cream formulation is considered extremely unlikely due to negligible systemic absorption.
Required Action Individuals must seek immediate medical attention and/or contact a Poison Help line when overexposure is suspected.
Severity Context The documented symptoms are generally non-life-threatening. No specific severe or life-threatening organ complications are explicitly detailed as acute overdose outcomes in the labeling.

The necessity to seek immediate medical attention is the mandated regulatory action for managing any suspected overdosage.

Therapeutic Uses of Tyza

What Tyza Treats: Main Uses and Benefits

This therapeutic domain is commonly used across conditions presenting with chronic, deep-seated infections that may require systemic treatment, such as Onychomycosis (fungal infections of the fingernails and toenails) and Tinea capitis (scalp ringworm). The medication is applied in addressing the fungal pathogen at the source, supporting the cessation of nail plate deterioration, and contributing to the regrowth of healthy nail and hair. This may assist in addressing the underlying fungal pathogen in chronic infections and supports general well-being during symptomatic phases.

Tyza is considered relevant for extensive or recurrent dermatophytosis of the skin, including widespread Tinea corporis (body ringworm), Tinea cruris (jock itch), and severe Tinea pedis (athlete's foot). The medication helps manage symptom clusters involving scaly rashes, intense itching, redness, and inflammation. The main benefit is supporting the clearance of the infection, which contributes to easing the overall symptom load and may assist in reducing the likelihood of recurrence.

“The medication is applied when fungal manifestations are both visually disruptive and lead to persistent physical distress, requiring supportive symptom management.”


Quick Fact: Relief for Pruritus and Inflammation Tyza is used for managing the pervasive itching (pruritus), burning, and inflammation associated with active fungal skin infections, helping to improve day-to-day comfort.

Regulatory References

  1. NIH MedlinePlus overview of Terbinafine

Eligibility and Restrictions for Use

Eligibility for Tyza (Terbinafine) Oral Tablets

Official regulatory documents define strict limitations on who can and cannot use Tyza oral tablets, primarily based on underlying health conditions and age.

Classification Population/Condition
Absolute Contraindication Patients with chronic or active liver disease
Absolute Contraindication Known hypersensitivity to terbinafine or any component of the tablet
Use Not Recommended Patients with severe renal impairment (creatinine clearance <50 mL/min)
Use Not Recommended Nursing mothers (excreted into breast milk)
Conditional Use Pregnant women (only if benefits clearly outweigh potential risks)
Use Not Established Patients younger than 18 years for treating onychomycosis

Use is generally approved for adults and for children weighing over 40 kg for specific indications. However, the possibility of pre-existing kidney or liver function impairment must be considered for older adults (65 years and above). Additionally, the label advises caution for patients with pre-existing conditions like Psoriasis or Lupus Erythematosus, as these conditions have been reported to worsen during treatment.

What should I know about interactions with other medicines?

Interaction Map: Tyza Interactions with other medicines and products — official regulatory information

The interaction profile for Terbinafine Hydrochloride (Tyza) is defined by its substantial effect on specific drug-metabolizing enzymes.


Interaction Scope

Terbinafine is officially designated as a potent inhibitor of the CYP450 2D6 isozyme. This potent inhibitory action may convert an individual's natural metabolic status to a poor metabolizer phenotype for other co-administered substances. This interaction is noted to affect the clearance of entire drug classes, including Tricyclic Antidepressants, certain beta-blockers, SSRIs, and Antiarrhythmics.

Exposure Modification and Restrictions

The clearance of Terbinafine itself is subject to significant alteration by other medications. Regulatory documents confirm that co-administration with the inducer Rifampicin dramatically increases Terbinafine's clearance by 100%. Conversely, Fluconazole (a dual inhibitor) is documented to increase Terbinafine's exposure, raising the Area Under the Curve (AUC) by 69%. Cimetidine also reduces Terbinafine's clearance by approximately 30%. In addition, co-administration with Warfarin requires close monitoring of the International Normalized Ratio (INR) due to rare, documented fluctuations. The drug is contraindicated in patients with active or chronic hepatic disease due to this metabolic profile.

Mechanism of Action

Tyza's mechanism of action is fungicidal, resulting in the death of the fungal pathogen by targeting the cell structure and metabolism. The drug's core action is strictly focused on the enzyme squalene epoxidase (SQLE), a vital enzyme in the fungal ergosterol synthesis pathway.


Dual-Action Mechanism on Fungal Cell Structure

The drug executes a dual mechanism by acting as a non-competitive inhibitor of Squalene Epoxidase. This specific molecular block achieves two simultaneous physiological consequences within the fungal cell. First, the essential structural component ergosterol is critically depleted, directly weakening the fungal cell membrane's integrity. Second, the precursor molecule squalene accumulates to toxic concentrations inside the cell, poisoning the organism internally. These two actions—membrane destabilization and internal toxicity—combine to cause cell lysis and death, resulting in the drug's fungicidal activity.


Selectivity and Tissue Localization

The mechanism exhibits high fungus-specific selectivity, demonstrating a higher affinity for the fungal Squalene Epoxidase enzyme than for the analogous mammalian enzyme involved in cholesterol synthesis. The drug's physical properties allow it to concentrate and persist in keratinous tissues (skin, hair, and nails), facilitating the execution of the fungicidal mechanism in these areas.

Dosage and Administration Information

Tyza (Terbinafine) is officially administered using two distinct routes based on the target infection: an oral tablet for systemic treatment of deep-seated infections and a 1% cream or solution for topical cutaneous application. The overall usage pattern is standardized and requires the medication to be taken over a fixed, time-bound course.

The core systemic regimen for adults involves taking one 250 mg tablet once daily. This consistent once-daily frequency is required to maintain adequate levels, and the tablet may be ingested with or without food. If the oral granules formulation is used, instructions specify they must be sprinkled onto a spoonful of soft, non-acidic food, such as pudding or mashed potatoes, and swallowed immediately without chewing to ensure correct administration.

The duration of the systemic treatment course is predetermined by the infection site and is not flexible. For fungal infections of the fingernail, the official course duration is typically six weeks, while infections affecting the toenails require treatment for a full twelve weeks. Completing the entire prescribed duration is essential for achieving the intended therapeutic goal, even if visible signs of infection begin to clear earlier.

Specific dosing guidance applies to certain populations. Pediatric patients often follow a weight-based dosing schedule for the systemic tablet or granules, with doses ranging from 125 mg to 250 mg. Furthermore, the use of oral Tyza is generally not recommended in individuals with pre-existing severe renal or active chronic hepatic impairment. Topical preparations, intended solely for external use, are applied in a thin layer once or twice daily for shorter durations (typically one to two weeks).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tyza


Evidence for use in Fungal Skin Infections (e.g., Ringworm, Athlete’s Foot, Jock Itch)

This section summarizes the structure of available clinical research, including short-term trials and observational studies, that have investigated the use of Tyza for common fungal skin conditions. Studies were conducted during periods of increased symptom activity and explored how symptoms related to physical discomfort and irritative states changed over defined time intervals.

The research primarily involved short-term randomized controlled trials (RCTs) of adult populations with mild to moderate conditions. Outcomes related to physical discomfort and patient-reported outcomes were monitored. Findings describe patterns observed in the studies related to changes in symptom expression.

Follow-up durations were limited in these studies, meaning that the long-term characterization or recurrence of these conditions is not fully established. While findings indicate patterns related to the monitored outcomes, certainty remains low due to modest sample sizes in many trials. Research provides insight into short-term changes, but results apply only to the populations studied.


Evidence for use in Fungal Nail Infections (Onychomycosis)

This part presents the research focused on the systemic use of Tyza for fungal infections of the fingernails and toenails, describing the types of studies that have examined reported measurements over extended treatment periods. Studies required longer observation times, exploring outcomes reflecting daily functioning.

Research examined how symptoms evolved, and findings describe patterns observed related to nail appearance and changes in measurements of the fungus over the course of several months. Evidence contributes to understanding symptom patterns, and some research highlights changes measured during the study period.

The primary limitation is that data are still emerging, and evidence quality varies across studies. The full extent of observed changes related to Tyza over an extended period is not fully established. Comparative evidence with other treatments is sometimes lacking, and subgroup findings regarding specific types of nail infections are uncertain.


Long-term Follow-up and Durability of Findings

This section summarizes what is characterized and what remains unclear regarding the duration of reported outcomes, including any available data on long-term follow-up beyond the initial treatment phase.

Generally, there is limited information for long-term outcomes following the end of the observed treatment periods for both skin and nail conditions. Data showing patterns related to the sustained evolution of the condition or the persistence of reported outcomes remain insufficient. Certainty remains low regarding what has been characterized years after the study concludes.


Research in Special Populations

This area outlines what studies have evaluated special groups where research may be limited, specifically describing what is known about the use of Tyza in children and older adults, as well as those with comorbid conditions like pre-existing liver or kidney conditions.

Populations included were typically restricted to adults. Consequently, data for certain groups, such as children or pregnant populations, remain insufficient. Tyza was evaluated in studies for older adults, but sample sizes were modest; results apply only to the populations studied, and certainty remains low for extrapolation beyond these specific groups.


What is Still Uncertain About Tyza

A primary area of uncertainty is the consistency of reported outcomes, as findings were mixed across various studies, and evidence quality varies. Overall, the certainty remains low regarding the full range of potential long-term effects and the consistency of outcomes across all patient types.

Frequently Asked Questions (FAQ)

Common questions about Tyza (FAQ)

Q: Can Tyza be used by children?

Official product information states that oral terbinafine is approved for use in children aged four years and older for specific types of fungal infections, such as tinea capitis (scalp infection). The dose for pediatric patients is generally determined based on the child's weight. The final indications and eligibility for use in pediatric patients are confirmed by the prescribing physician.


Q: Are there any common foods or drinks to avoid while using Tyza?

According to official information, the oral tablet may increase the level of caffeine in the body, which can lead to side effects like headache or agitation. For this reason, official information advises that the intake of products containing caffeine, such as coffee, tea, cola, and chocolate, should be limited while using the medication.


Q: Do the side effects of Tyza go away over time?

While many common side effects, such as gastrointestinal upset, may resolve or lessen as the body adjusts to the medication, some serious effects are documented to be prolonged. The official labeling highlights that taste and smell disturbances have been reported to be severe and, in rare instances, permanent.


Q: Can older adults (seniors) safely use Tyza?

Official product labeling indicates that use in adults aged 65 years and older is subject to caution. Regulatory labeling notes that pre-existing conditions, such as decreased kidney or liver function, are clinical factors for the prescriber to consider. Potential drug interactions are also noted as a factor in this population.


Q: Is it normal to feel a little different when first starting Tyza?

Common adverse reactions are known to occur, often at the beginning of therapy, and may cause a person to feel different. These frequently reported effects include general symptoms like headache, diarrhea, nausea, abdominal pain, or other gastrointestinal upset.


Q: Why is Tyza not recommended for people with [Specific common contraindication]?

The medication is contraindicated in patients with chronic or active liver disease because cases of liver failure, sometimes resulting in death or liver transplant, have been reported with oral terbinafine. The risk of liver damage is a major regulatory concern described in the official warnings.


Q: What are the long-term risks associated with taking Tyza?

The treatment is intended for a fixed, time-bound course, and data characterizing effects many years after completion are limited. However, official labeling highlights that taste disturbance, including loss of taste, may be prolonged or permanent. Rare but serious risks such as liver failure have also been reported and are categorized as Warnings and Precautions.


Q: Can a patient stop taking Tyza suddenly?

Regulatory documents emphasize the importance of completing the entire prescribed duration of treatment. Stopping the medication too soon, even if visible signs of the infection are clearing up, may lead to the infection returning or not fully resolving.


Q: Does Tyza require regular blood tests for monitoring?

Yes, the prescribing information states that liver function tests (blood tests) are generally required before starting oral terbinafine. Due to the reported risk of liver damage (hepatotoxicity), official authorities advise that periodic monitoring of liver function be considered during the course of therapy.


Q: Is Tyza the same type of medicine as [Name of common similar drug]?

The active ingredient in Tyza, terbinafine, is officially classified as a synthetic allylamine antifungal agent. This classification describes the specific pharmacological group the medicine belongs to.


Q: How quickly can someone typically feel the effects of Tyza?

Fungal infections, particularly nail infections, are generally slow to clear up. Official information indicates that clinical improvement is a gradual process that can take several weeks or months, depending on the site of the infection being treated.


Q: Do you need a special prescription to get Tyza?

The oral tablet form of Tyza is a prescription-only medication. However, the topical cream or solution forms of terbinafine are available over-the-counter for localized skin infections, in addition to being available by prescription.


Q: Does taking Tyza cause weight gain or loss?

Weight changes are not commonly listed as a direct side effect of the medication. However, official documentation notes that weight loss may occur as an indirect consequence of taste or smell disturbances, which can sometimes be severe enough to cause a decreased desire for food.


Q: Does Tyza have a Black Box Warning?

The official labeling includes numerous serious warnings, categorized under 'Warnings and Precautions.' These include the risk of liver failure, severe skin reactions, and potential taste disturbance. These are noted as critical risks to be aware of before and during treatment.


Q: Are there any herbal supplements that are known to interact with Tyza?

There is insufficient information to state that the majority of herbal remedies and supplements are safe to take with oral terbinafine, as these products are not typically subject to the same rigorous testing as prescription medicines. Patients are encouraged to review all supplements they take with a healthcare professional.


Q: Is Tyza available as a generic medicine?

Yes, the FDA has approved generic versions of terbinafine hydrochloride tablets. The availability of a generic version can sometimes affect cost and insurance coverage, but the active ingredient remains the same.


Q: What if someone experiences a very rare side effect from Tyza?

Official labeling describes the serious events that warrant immediate medical attention, such as signs of liver injury, taste/smell disturbance, or a progressive skin rash. Additionally, the FDA provides a patient reporting system (MedWatch) for suspected adverse reactions.


Q: Does Tyza interact with birth control pills?

Clinical studies suggest a negligible potential for terbinafine to significantly interfere with the metabolism of most oral contraceptives. However, post-marketing reports have noted some cases of menstrual irregularities, such as breakthrough bleeding, in patients taking both medications.


Q: Can Tyza affect a person's mood or behavior?

Official documents indicate that depressive symptoms have been reported during postmarketing use of oral terbinafine. Official warnings state that patients should be alert to and inform their prescriber about the development of depressive symptoms.


Q: Does Tyza interact with alcohol?

Official warnings indicate that terbinafine is associated with a risk of liver problems, which is a serious adverse event. Since drinking alcohol may increase this risk of damage to the liver, the prescribing information advises that patients discuss alcohol consumption with their healthcare provider.

How should Tyza be stored and disposed of?

Storage and Handling Requirements

Tyza (Terbinafine) oral tablets must be stored at controlled room temperature, typically 20 C to 25 C. All formulations must be stored away from excess heat and moisture and protected from light. The medication must be kept from freezing; additionally, the topical cream should not be refrigerated.

Keep the product in its original container with the lid tightly closed to maintain product stability and protect it from environmental factors. The topical cream, once opened, has a labeled shelf-life of 28 days.

For child safety, the medicine must be stored out of the sight and reach of children.

Official Disposal Instructions

Disposal of unused or expired Tyza must be carried out in accordance with local/regional regulations. Patients are advised to consult a healthcare professional regarding disposal or utilize a community drug take-back program. It is explicitly required to avoid release to the environment because Terbinafine is classified as very toxic to aquatic life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tyza found in:

A-Z Index: